Evidence map›Paper›PMID 32450244›Full record

SynthesisChest2020

Clinical Phenotypes of Atopy and Asthma in COPD: A Meta-analysis of SPIROMICS and COPDGene.

Nirupama Putcha, Ashraf Fawzy, Elizabeth C Matsui, Mark C Liu, Russ P Bowler, Prescott G Woodruff, Wanda K O'Neal, Alejandro P Comellas, MeiLan K Han, Mark T Dransfield and 18 more

Registry-linked trialOpen access · greenAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Chest, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01969344 (Subpopulations and Intermediate Outcome Measures in COPD Study), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01969344 active not recruitingnot on this map

Subpopulations and Intermediate Outcome Measures in COPD Study

TypeobservationalSponsorUniversity of North Carolina, Chapel HillRan2010 to 2031Enrolled2,981ConditionsCOPD, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Asthma and respiratory comorbidities.The Journal of allergy and clinical immunology · 2025
    Review
  3. Article
  4. Polymorphisms in theJournal of thoracic disease · 2023
    Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. The Role of Atopy in COPD and Asthma.Frontiers in medicine · 2021
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 19 institutions in 1 country.

Nirupama PutchaDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: Nputcha1@jhmi.edu.
Ashraf FawzyDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Elizabeth C MatsuiDepartments of Population Health and Pediatrics, Dell Medical School at the University of Texas at Austin, Austin, TX.
Mark C LiuDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Russ P BowlerDivision of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO.
Prescott G WoodruffDivision of Pulmonary, Critical Care and Sleep, University of California San Francisco, San Francisco, CA.
Wanda K O'NealUniversity of North Carolina Marsico Lung Institute, Chapel Hill, NC.
Alejandro P ComellasDivision of Pulmonary, Critical Care and Occupational Medicine, University of Iowa, Iowa City, IA.
MeiLan K HanDivision of Pulmonary and Critical Care Medicine, University of Michigan School of Medicine, Ann Arbor, MI.
Mark T DransfieldDivision of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, University of Alabama Birmingham Lung Health Center, and Birmingham Veterans' Affairs Medical Center.
J Michael WellsDivision of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, University of Alabama Birmingham Lung Health Center, and Birmingham Veterans' Affairs Medical Center.
Njira LugogoDivision of Pulmonary and Critical Care Medicine, University of Michigan School of Medicine, Ann Arbor, MI.
Li GaoDivision of Allergy and Clinical Immunology, Johns Hopkins University, Baltimore, MD.
C Conover TalbotThe Johns Hopkins School of Medicine Institute for Basic Biomedical Sciences, Baltimore, MD.
Eric A HoffmanDivision of Pulmonary, Critical Care and Occupational Medicine, University of Iowa, Iowa City, IA.
Christopher B CooperDivision of Pulmonary and Critical Care, University of California Los Angeles, Los Angeles, CA.
Laura M PaulinSection of Pulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center/Geisel School of Medicine at Dartmouth, Lebanon, NH.
Richard E KannerDivision of Pulmonary and Critical Care, University of Utah School of Medicine, Salt Lake City, UT.
Gerard CrinerDepartment of Pulmonary, Temple University Philadelphia, PA.
Victor E OrtegaDepartment of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC.
R Graham BarrDivision of General Internal Medicine, Columbia University Medical Center, New York, NY.
Jerry A KrishnanDivision of Pulmonary, Critical Care, Sleep and Allergy, University of Illinois at Chicago, Chicago, IL.
Fernando J MartinezCornell University School of Medicine, New York, NY.
M Bradley DrummondDivision of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Robert A WiseDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Gregory B DietteDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Craig P HershChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA.
Nadia N HanselDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Johns Hopkins University · USJohns Hopkins Medicine · USBirmingham VA Medical Center · USMichigan Medicine · USUniversity of Iowa · USBrigham and Women's Hospital · USColumbia University Irving Medical Center · USCornell University · USDartmouth–Hitchcock Medical Center · USLung Institute · USNational Jewish Health · USTemple University · USThe University of Texas at Austin · USUniversity of California, Los Angeles · USUniversity of California, San Francisco · USUniversity of Illinois Chicago · USUniversity of North Carolina at Chapel Hill · USUniversity of Utah · USWake Forest University · US

Funding

Genetic Epidemiology of COPDU01HL089897 · NHLBI · NATIONAL JEWISH HEALTH · PI CRAPO, JAMES D · 2007 to 2021
$56.9M
Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5M
SPIROMICS II: Biological underpinnings of COPD heterogeneity and progressionU01HL137880 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOODRUFF, PRESCOTT G · 2017 to 2021
$27.9M
Genetic Epidemiology of COPDU01HL089856 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SILVERMAN, EDWIN K · 2007 to 2021
$20.7M
SPIROMICS GIC SupportU24HL141762 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID J, O'NEAL, WANDA K · 2018 to 2022
$7.2M
Scientific & Technical CoreP2CHD042849 · NICHD · UNIVERSITY OF TEXAS AT AUSTIN · PI Catherine A Calder · 2017 to 2026
$5.2M
The Environmental Assessments Core (FSC)P50MD010431 · NIMHD · JOHNS HOPKINS UNIVERSITY · PI HANSEL, NADIA N · 2015 to 2019
$3.5M
SYSTEMS GENOMICS OF THE ASTHMA-COPD OVERLAP SYNDROMER01HL130512 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HERSH, CRAIG P · 2016 to 2019
$3.5M
INTEGRATIVE GENOMICS OF CLINICAL SUBTYPES IN COPDGENER01HL125583 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HERSH, CRAIG P · 2015 to 2018
$3.5M
Clinical trial of air cleaners to improve indoor air quality and COPD healthR01ES022607 · NIEHS · JOHNS HOPKINS UNIVERSITY · PI HANSEL, NADIA N · 2013 to 2017
$3.4M
Mentoring in Patient-Oriented Research on Asthma and the Indoor EnvironmentK24AI114769 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI MATSUI, ELIZABETH C. · 2015 to 2023
$1.6M
Mentoring Research in Precision Medicine for Lung DiseaseK24HL137013 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRESCOTT G WOODRUFF · 2017 to 2026
$1.2M
NHLBI NIH HHS HHSN268200900013CNHLBI NIH HHS HHSN268200900014CNHLBI NIH HHS HHSN268200900015CNHLBI NIH HHS HHSN268200900016CNHLBI NIH HHS HHSN268200900017CNHLBI NIH HHS HHSN268200900018CNHLBI NIH HHS HHSN268200900019CNHLBI NIH HHS HHSN268200900020CNHLBI NIH HHS K23 HL123594NHLBI NIH HHS K24 HL137013NHLBI NIH HHS R01 HL125583NHLBI NIH HHS R01 HL130512NHLBI NIH HHS U01 HL089856NHLBI NIH HHS U01 HL089897NHLBI NIH HHS U01 HL137880NHLBI NIH HHS U24 HL141762NIAID NIH HHS K24 AI114769NICHD NIH HHS P2C HD042849NIEHS NIH HHS P30 ES005605NIEHS NIH HHS R01 ES022607NIMHD NIH HHS P50 MD010431
6 · The paper itself

Abstract

backgroundLittle is known about the concordance of atopy with asthma COPD overlap. Among individuals with COPD, a better understanding of the phenotypes characterized by asthma overlap and atopy is needed to better target therapies. RESEARCH QUESTION: What is the overlap between atopy and asthma status among individuals with COPD, and how are categories defined by the presence of atopy and asthma status associated with clinical and radiologic phenotypes and outcomes in the Genetic Epidemiology of COPD Study (COPDGene) and Subpopulation and Intermediate Outcome Measures in COPD Study (SPIROMICS)? STUDY DESIGN AND

methodsFour hundred three individuals with COPD from SPIROMICS and 696 individuals from COPDGene with data about specific IgEs to 10 common allergens and mixes (simultaneous assessment of combination of allergens in similar category) were included. Comparison groups were defined by atopic and asthma status (neither, atopy alone, atopic asthma, nonatopic asthma, with atopy defined as any positive specific IgE (≥0.35 KU/L) to any of the 10 allergens or mixes and asthma defined as self-report of doctor-diagnosed current asthma). Multivariable regression analyses (linear, logistic, and zero inflated negative binomial where appropriate) adjusted for age, sex, race, lung function, smoking status, pack-years smoked, and use of inhaled corticosteroids were used to determine characteristics of groups and relationship with outcomes (exacerbations, clinical outcomes, CT metrics) separately in COPDGene and SPIROMICS, and then adjusted results were combined using meta-analysis.

resultsThe prevalence of atopy was 35% and 36% in COPD subjects from SPIROMICS and COPDGene, respectively, and less than 50% overlap was seen between atopic status with asthma in both cohorts. In meta-analysis, individuals with nonatopic asthma had the most impaired symptom scores (effect size for St. George's Respiratory Questionnaire total score, 4.2; 95% CI, 0.4-7.9; effect size for COPD Assessment Test score, 2.8; 95% CI, 0.089-5.4), highest risk for exacerbations (incidence rate ratio, 1.41; 95% CI, 1.05-1.88) compared with the group without atopy or asthma. Those with atopy and atopic asthma were not at increased risk for adverse outcomes.

interpretationAsthma and atopy had incomplete overlap among former and current smokers with COPD in COPDGene and SPIROMICS. Nonatopic asthma was associated with adverse outcomes and exacerbation risk in COPD, whereas groups having atopy alone and atopic asthma had less risk.

Indexed as

Asthma-Chronic Obstructive Pulmonary Disease Overlap SyndromeHypersensitivity, ImmediateImmunoglobulin EPulmonary Disease, Chronic ObstructiveStatus AsthmaticusBiological Variation, PopulationDisease ManagementFemaleHumansMaleMiddle AgedMolecular EpidemiologyPrevalenceRisk FactorsSmokingImmunoglobulin Easthma COPD overlapatopyCOPD

Identifiers

PMID32450244
PMCPMC7768932
OpenAlexW3026733562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.